Research Hotspots of Clinical Trials of Anti-Tumor Drugs in China
Objective To summarize the research hotspots of clinical trials of anti-tumor drugs in China.Methods The information on the clinical trials of anti-tumor drugs excluding bioequivalence tests registered on the Drug Clinical Trial Registration and Information Disclosure Platform in China(not including relevant information of Hong Kong,Macau and Taiwan)from 2013 to 2020 was extracted,including drug type,clinical trial phases,drug targets,sponsors,institutions,etc.The Gephi 0.9.2 software was used to generate social network cooperative diagrams.Results A total of 2 143 clinical trials of anti-tumor drugs were included.There were fewer clinical trials in 2014 and 2015(97 ones,104 ones),while those increased year by year since 2016,from 211 to 477 ones.Among them,the majority were focused on chemical drugs(1 238 ones),and the phase Ⅰ clinical trials were the most(951 ones).There were 99 drug targets involved(excluding undisclosed ones),and the top three involving more drug clinical trials were the programmed death-1/programmed death-ligand 1(PD-1/PD-L1,281 ones,13.11% ),epidermal growth factor receptor(128 ones,5.97% )and human epidermal growth factor receptor 2(79 ones,3.69% ).The indications for clinical trials were mainly solid tumors(389 ones),lung cancer(382 ones),breast cancer(239 ones),lymphoma(229 ones),and liver cancer(148 ones).A total of 722 sponsors established cooperative relationships with 617 drug clinical trial institutions.The sponsors conducted more clinical trials of anti-tumor drugs were the Jiangsu Hengrui Pharmaceutical Co.,Ltd.,Shanghai Hengrui Pharmaceutical Co.,Ltd.and Chiatai Tianqing Pharmaceutical Group Co.,Ltd.,and the institutions conducted more clinical trials were the Peking University Cancer Hospital,Henan Cancer Hospital,Cancer Hospital Affiliated to Harbin Medical University.Conclusion PD-1/PD-L1 is the most popular drug target in the field of targeted therapy for tumors.When conducting clinical trials of anti-tumor drugs,it is important to closely follow the policies,regulations,and guiding principles related to research and development(R&D)and registration of new drugs in China,and pay attention to the R&D of innovative or improved cancer drugs with clinical value.
anti-tumor drugclinical trial of drugtarget of drugsocial network analysisresearch and development of new drug
国家科技期刊平台
NSTL
万方数据
